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vABSTRACT
COST-UTILITY OF PROSTATE CANCER SCREENING
Bill Fell
May 13, 2006
Prostate cancer is a common form of cancer in men.  In fact, prostate cancer has
the highest incidence of any cancer in men.  Prostate cancer is not only common, it
carries a significant financial burden.  The cost of prostate cancer is 11.3% of all cancer
expenditures.  If after a DRE the prostate is enlarged, or if the PSA is elevated, then a
biopsy of the prostate would be recommended.  Under the best of circumstances, cancer
diagnoses will be missed and many will undergo unnecessary biopsy, etc. 
The focus of this paper was the cost-utility of screening with the PSA test.  The
cost differences between screening and not screening was compared.  A Markov analysis
and a Monte Carlo simulation were utilized to provide a basis for conclusion.
The primary finding is that the costs associated with screening are much higher
than those of not screening.  Additional findings are that the specificity of the PSA test,
the first year treatment costs, and the utility/outcomes of screening have an impact on the
cost-utility of screening.  The conclusion, however, is that the improvements in these
factors would have to be significant to impact the case for screening.  Until longitudinal
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The prostate is a cluster of glands located at the base of the bladder, centered
between the base of the penis and the rectum (Figure 1)1.  The prostate surrounds the
urethra.  The urethra, the tube through which urine travels from the bladder through the
penis to be eliminated from the body, courses through the prostate.  The primary function
of the prostate is to produce the majority of seminal fluid.  This fluid facilitates transport
and nourishment of sperm.  During ejaculation, the prostate squeezes fluid into the
urethra.
Figure 1.  Male Genito-Urinary Anatomy
2Prostate Diseases
There are three main diseases that can occur concerning the prostate.2  The first is
prostatitis.  Prostatitis is the inflamation of the prostate gland.  It can be caused by an
infection or irritation of the prostate.  The second is benign prostatic hyperplasia (BPH). 
BPH is the enlargement of the prostate.  BPH manifests as men age and it may be a
natural occurrence.  From age 49 to age 80, the prevalence of BPH appears to increase
linearly.3  The third is prostate cancer, the growth of a tumor in the prostate gland.  Other
diseases such as prostatodynia (non-infection, non-inflamation prostatitis) and prostatic
stones are less significant.
Prostate Cancer
Prostate cancer is a common form of cancer in men and is generally a slow
growing cancer.  Prostate symptoms often do not present themselves until the tumor is
large in size, locally invasive, or until the cancer metastasises.  The symptoms include
difficulty urinating, a weak stream when urinating, frequent urge to urinate (especially
during the night) painful or burning urination, and blood in the urine.4  Unfortunately
prostatitis and BPH share theses symptoms.  If the cancer metastasises, the symptoms
may come from the secondary site.  The cancer may spread through the lymph nodes and
blood stream to the secondary site.  A common symptom of metastatic spread is lower
back pain.  This is caused by involvement of the lumbosacral spine.
In males, prostate cancer has the highest incidence of cancers.  Additionally,
prostate cancer trails only lung cancer in causes of death in men.5  In 2005, it was
estimated that 232,090 new cases of prostate cancer would be diagnosed and 30,350 men
would die from it.6  One in 6 will get the disease and one in 34 will die from the disease. 
3There are several risk factors associated with the incidence of prostate cancer.7  They are
age, African-American ethnicity, nationality, family history, diet, physical inactivity and
obesity, and vasectomy.  Of these, age and African-American ethnicity are the most
significant.  A majority (70%) of all new prostate cancers will be in men older than 65. 
The incidence for African-American men is 60% higher than the incidence for white
American men.  Family history is also a strong predictor.  If one has a father or brother
with prostate cancer, the probability of developing prostate cancer is higher.  In fact,
having a brother with prostate cancer carries a higher probability than having a father
with the disease.  Diet, physical activity and obesity, and vasectomy are not as strongly
correlated as the others.
Economic Perspective
From a cost standpoint let us put this cancer in perspective.  The Gross Domestic
Product (GDP) for the United State was 2005 was $12,486 billion.8  National healthcare
expenditures for 2004 totaled $1,540 billion.9  The direct annual medical cost of cancer
care in the U.S. for 2004 was estimated at $72.1 billion.10  This does not include any cost
of lost productivity due to illness or death.  The cost of prostate cancer was 11.1% of all
cancer expenditures11 or approximately $8.0 billion.  This means that the cost of prostate
cancer was approximately 0.064% of the U.S. GDP in 2005.  Prostate Cancer treatment is
moderately significant to other cancers in terms of cost.
Diagnosis
The diagnosis of prostate cancer can be accomplished in several ways.12 
Screening can be the initial step in the diagnostic process.  The patient could be screened
4by a digital rectal exam (DRE).  During a DRE, a physician places a finger in the male’s
rectum and palpates the prostate gland for size and shape.  If the size and/or shape are
found to be irregular, a biopsy of the prostate would be performed.  The biopsy is
considered the “gold standard” for diagnosing prostate cancer.13  Another screening
modality is measuring the amount of prostate-specific antigen in the blood (PSA).  PSA
is a protein that is normally produced in the prostate gland.14  The serum PSA level may
become elevated if the normal structure is disturbed due to cancer, BPH, or prostatitis.  If
the PSA is elevated, then a biopsy of the prostate is often recommended depending on the
clinical setting.15
When a patient presents with symptoms and has not been screened, the
recommended practice is to perform the DRE and/or the PSA as part of the diagnostic
work up and potentially continue to biopsy.  Transrectal ultrasound (TRUS) is often used
in conjunction with the biopsy.  As the work up progresses other diagnostic imaging
techniques may be employed, such as computerized tomography (CT scan) or magnetic
resonance imaging (MRI).
Treatment
Treatment is essentially one of four modalities or a combination of the them. 
They are surgical, radiation, medical hormonal, or observation.16  Surgical therapy is
either a radical or partial prostatectomy.  A radical prostatectomy involves removing the
entire prostate.  A partial prostatectomy removes only the affected area of the gland.  The
second treatment choice is radiation therapy.  This can be accomplished by placing a
radioactive “seed” in the prostate, or perhaps by using use of irradiation with an external
beam radiation.   A third option is medication therapy either through chemotherapy or
5hormonal therapy.  Finally, a treatment choice that has grown in popularity is the choice
not to have treatment at all.  This is sometimes called “watchful waiting.”  Many prostate
cancers are very slow growing and organ confined.  Therefore, some men elect to defer
or decline treatment.  Recognize this is not a passive process.  The patient continues to
undergo testing and biopsy until a final determination is made as to treat or not to treat.
The Issues
There are several issues that exist regarding the diagnosis and treatment of
prostate cancer.  The first issue to consider is that, for many men, prostate cancer is slow
growing.  Many males will go through life having prostate cancer, and they never have
significant symptoms.17  Compared to other cancers, the incidence in males is high.18  The
chance of a bad outcome does exist.  There is the inherent difficulty in accurately
predicting which affected person will be in the smaller percentage that has significant
morbidity and mortality.
The second issue is that the DRE and the PSA test are good predictors of prostate
cancer, but are not as accurate as we would like.19  The best sensitivity and specificity for
PSA is better than the DRE at 80% and 70% respectively.20,21,22  What this means is that
even under the best of circumstances, a cancer diagnosis will be missed in a fifth of males
with disease.  (Which is much worse than thought to be true.)  This also highlights that
about a third of the males that screen positive will undergo unnecessary biopsy and other
testing.  Diagnostic testing can be expensive, can be painful, and can produce undesirable
side-effects.
Finally, the treatment options have inherent problems.  The treatment of prostate
cancer may not produce a 100% cure rate.  In addition, the complications of treatment
6can be devastating to a man.  The treatments can leave a man incontinent or impotent or
both.  For this reason many are deciding to live with symptoms, with the potential for the
onset of symptoms, or with the possibility of a bad outcome.
Focus
Since the PSA has better sensitivity and specificity than the DRE, we will
consider the PSA to be the standard screening tool as compared to not screening at all. 
Serum PSA is the screening method recommended by established guidelines.23  The
paper was begun with the idea of focusing on the cost-utility of the PSA with respect to
outcomes.  As the literature search was undertaken, it was found that there were utility
studies that look at the quality-adjusted life-years or other measures,  available for
prostate cancer and treatment.  No connection was made between the improvement in
these utilities due to screening.24  Mortality and morbidity data are not available yet.  It is
expected that the utilities for the relationship between screening and outcomes will be
available between now and 2010.25  The focus of this paper is to study the factors that
affect the relationship of screening to outcomes.  The cost difference between
“screening” and “not screening” will be compared.  The aim is to develop a model for
this comparison and to simulate changes in pertinent factors to determine their affect on
the model.  When the data becomes available, the model can be re-engineered to
accommodate the updated information.
7LITERATURE REVIEW
Prostate Cancer and the Progression of Disease
Prostate cancer continues to be a significant disease in the male population. 
Prostate cancer is the leading cancer diagnosis and is the second leading cancer cause of
death in the United States in 2001, in men.26  In 2004, the American Cancer Society
estimated that prostate cancer would lead in new cancer diagnoses at 230,110.  Prostate
cancer would be the second leading cause of cancer death, second to lung, at 29,500
deaths.27  This ranking remains true as the leader of new cancers with 232,090 prostate
cancer cases for American males in 2005.  The estimates of causes of cancer deaths for
males for 2005 continue with the lung as number one and prostate as number two at
30,350 prostate cancer deaths.28  This data supports the fact that prostate cancer is a
common cancer diagnosis and a leading cause of cancer deaths in men.
Prostate cancer manifests in different ways.  It is often a very slow growing
tumor.29  An individual may have this cancer for many years without symptoms.  Lower
urinary tract symptoms (LUTS) are generally part of the progress of the disease.  These
symptoms are listed in Table 1.30  The symptoms can be of a flow restrictive nature or of
a bladder capacity nature.  LUTS can also be indicative of benign prostatic hyperplasia
(BPH), bladder outlet obstruction (BOO), prostatic stones, and prostatodynia.  BPH is a
benign enlargement of the prostate that occurs as men age.  BPH is so common it could
be considered normal.31  On autopsy, 50% of men in their 50's and 90% of men in their
890's have BPH.
Table 1.






Terminal and postmicturitional dribble
Dysuria





The incidence rates of LUTS/BPH are in Table 2.32  BOO can be prostatic in origin or
from some other anomaly.  Prostatic stones, mineral deposits in the prostate, can cause
acute or chronic prostatitis.  Prostatodynia is pain in the prostate of unknown origin.
Lower back pain can be a symptom of prostate cancer as a result of metastasis.33 
In this case, the prognosis is poor.  The cancer originating in the prostate finds its way
into bones of the pelvis and the lumbar spine.  In fact, metastatic prostatic cancer should




Age (years) Incidence per 1000man-years
50 - 54 6.91
55 - 59 13.02
60 - 64 19.78
65 - 69 23.99
70 - 74 34.46
75 - 79 38.30
80 - 84 32.20
Finally, prostate cancer can result in death.  However, because of the disease’s
slow growth, a man will probably die “with” prostate cancer rather than die “from”
prostate cancer.34  So, prostate cancer can manifest in a range from asymptomatic to
death.
Screening
There are basically two methods for screening for prostate cancer.  The digital
rectal exam (DRE) and the prostate-specific antigen test (PSA).35  The DRE is an exam
where the physician palpates the male’s prostate through the rectum.  The exam is
performed to detect enlargement, irregularity, and texture of the prostate that could
indicate prostate cancer.  PSA is a protein that is a normal product of the tissue in the
prostate.  The PSA test measures the level of prostate-specific antigen in the blood.  An
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elevated PSA can indicate prostate cancer, BPH, infection, or inflamation of the prostate.
The accuracy of the DRE and PSA tests is measured by the specific test’s
sensitivity and specificity.  The sensitivity of a test is the number of true positive tests
divided by the sum of the true positive tests and the false negative tests of who were
tested.  Expressed another way, the number of those that test positive and have the
disease divided the total number that have the disease.  The specificity of a test is the
number of true negative tests divided by the sum of the true negative tests and the false
positive tests of who were tested.  In general terms, the number of those that test negative
and do not have the disease divided the total number that do not have the disease.36
The sensitivity and the specificity of the DRE are not certain.37  According to
Coley, et al, the studies assessing the sensitivity and specificity are biased.  No studies
directly assessing the sensitivity and the specificity of the DRE in the last six years could
be located within this literature search.
The studies focused on the sensitivity and the specificity of the PSA are
summarized in the ranges 67.5% to 80% and 60% to 70%, respectively, at greater than 4
nanograms per milliliter (> 4ng/ml).38  Clinically, a PSA range of 0 to 4 ng/ml is
considered normal.39  At values less than 4ng/ml, the sensitivity and specificity is
generally low.40  However, age specific ranges for the PSA concentration improve the
sensitivity and specificity of the test.41  The PSA specificity can vary with age, ethnicity,
or national origin.  In practice, 4ng/ml is the cut-off.42  It is also important to consider that
the higher the PSA the more strongly prostate cancer or prostatitis should be suspected.
Different, or variant methods of screening for prostate cancer have been, and are
being, researched.  One such is the ratio of serum complexed PSA (cPSA) to serum total
PSA (tPSA).43  Increased cPSA is indicative high risk.  At lower levels of tPSA, detection
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of cancer may be improved.  In specific patients with co-morbidities such as end-stage
renal disease, tPSA augmented by PSA density and transrectal ultrasound (TRUS) has
shown improved detection.44  In specific populations, the use of multiple biomarkers has
shown some promise.  In one study, the detection was reported improved using serum
human glandular kallikrein 2 (jK2), tPSA, and free PSA (fPSA).45  New methods such as
PSA RapidScreen tests may improve availability and specificity of the screen.46  Another
tool that has been advocated is the PSA “velocity.”  This method evaluates the rate of
increase of the serum PSA over time.  The faster the rise the more suggestive of cancer. 
In fact, a doubling or tripling even withing the “normal” range can indicate an area of
concern.47  The amount of Medicare reimbursement for a PSA screen currently is
$25.70.48 
Diagnosis
A person enters the diagnostic phase by either screening positive or developing
symptoms.  Once either of these has occurred, as stated earlier, a biopsy is performed. 
The biopsy is considered the “gold standard.”  Unfortunately, as with any test, it is
possible to obtain a false negative.  When performing a sextant biopsy, there is a risk of
between 15% and 34% false negative procedures.49  For this reason, it is recommended
that as many as 30 biopsies be performed.  Nonetheless, biopsy is considered the




The breakdown of treatment preferences is not well documented.  In a Louisiana
study, the mix was 41.4% radical prostatectomy, 29.7% radiation therapy, 16.2%
hormonal therapy, and 11.9% watchful waiting.51  The spectrum of complications from
any of these treatment choices includes lymphocele formation; injuries to the ureter,
rectum, and urethra; prostatic necrosis; vesicourethral anastomotic leak and stricture;
urethral stricture, necrosis, and fistula; radiation proctitis; transient bladder outlet
obstruction; radiation-induced urethritis; urinary incontinence; and erectile dysfunction.52 
The average cost of the first year of treatment is $11,000.00.53
Recommendation
As of the latest update, September 12, 2005 to the Guidelines for Prostate
Screening at the National Guideline Clearinghouse54, the American Cancer Society
(ACS), the University of Michigan Health System (UMHS), and the U.S. Preventative
Services Task Force (USPSTF) provide the recommendations as follows:
Table 3




Targeted screening/Screening tests/Informed decision-making
ACS recommends that both the PSA test and the DRE should be offered
annually beginning at age 50, to men who have a life expectancy of at least
10 years. Men at high risk should begin testing at age 45. Information
should be provided to patients about benefits and limitations of testing.
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Specifically, prior to testing, men should have an opportunity to learn
about the benefits and limitations of testing for early prostate cancer
detection and treatment.
High-risk groups include men of African descent (specifically,
sub-Saharan African descent) and men with a first-degree relative
diagnosed at a young age. Risk increases with the number of first-degree




Modality.  PSA and DRE. Both have specificity limitations.
Initiate.  Clinicians who screen for prostate cancer should share decision
making with patients, giving objective information about the potential
risks and benefits of screening.
! Average risk. For men >age 50, consider initiating PSA screen.
! High-risk. For men with positive family history and for African
Americans, consider starting PSA screening at age 40.
Frequency.  Annually
Terminate.  Stop when life expectancy is less than 10 to 15 years.
There is considerable controversy surrounding screening for prostate
cancer. Early detection and treatment may avert future prostate
14
cancer-related illness, but treatment includes some risk of sexual
dysfunction and incontinence and a small risk of treatment-induced
mortality. At this time, no trials of sufficient power are available to
document the benefit of aggressive treatment (e.g. surgery, radiation)
versus conservative management and hormonal therapy. Similarly, there is
no conclusive evidence that routine screening for prostate cancer is





USPSTF concludes that the evidence is insufficient to recommend for or
against routine screening for prostate cancer using PSA testing or DRE.
I recommendation.
The USPSTF found good evidence that PSA screening can detect
early-stage prostate cancer but mixed and inconclusive evidence that early
detection improves health outcomes. Screening is associated with
important harms, including frequent false-positive results and unnecessary
anxiety, biopsies, and potential complications of treatment of some
cancers that may never have affected a patient's health. The USPSTF
concludes that evidence is insufficient to determine whether benefits
outweigh harms for a screened population.
Clinical Considerations
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! PSA testing and DRE can effectively detect prostate cancer at early
pathologic stages. There is insufficient evidence, however, that the
currently available treatments (radical prostatectomy, radiation
therapy, or hormonal therapy) reduce morbidity and mortality from
early prostate cancer. Therefore, the benefit of screening for and




! Despite the absence of firm evidence of effectiveness, some
clinicians may opt to perform screening for other reasons. Given
the uncertainties and controversy surrounding prostate cancer
screening, clinicians should not order the PSA test without first
discussing with the patient the potential but uncertain benefits
(reduction of morbidity and mortality from prostate cancer) and the
possible harms (false-positive results, unnecessary biopsies, and
possible complications of treatment) of prostate cancer screening.
Men should be informed of the gaps in the evidence, and they
should be assisted in considering their personal preferences and
risk profile before deciding whether to be tested.
! If early detection improves health outcomes, the population most
16
likely to benefit from screening will be men aged 50-70 years who
are at average risk, and men over age 45 who are at increased risk
(African American men and men with a family history of a
first-degree relative with prostate cancer).  Benefits may be smaller
in Asian Americans, Hispanics, and other racial and ethnic groups
that have a lower risk of prostate cancer. Older men and men with
other significant medical problems who have a life expectancy of
fewer than 10 years are unlikely to benefit from screening.
! PSA testing is more sensitive than DRE for the detection of
prostate cancer. PSA screening with the conventional cut-point of
4.0 ng/dl detects a large majority of prostate cancers; however, a
significant percentage of early prostate cancers (10-20%) will be
missed by PSA testing alone. Using a lower threshold to define an
abnormal PSA detects more cancers at the cost of more false
positives and more biopsies.
! The yield of screening in terms of cancer detected declines rapidly
with repeated annual testing. If screening were to reduce mortality,




In the literature there are papers on the utilities of treatment, but there seems to be
nothing currently demonstrating that outcomes are related to screening.  No data is
available, regardless of treatment, to demonstrate that the probabilities of mortality and
morbidity are improved or not improved by screening.  Within the next five years, data
are expected to be coming from the European Randomized Study of Screening for
Prostate Cancer (ERSPC).55  This is a longitudinal study that spans over a decade.  Data
are being collected within this study with respect to the outcomes as affected by
screening.
18
GOAL, OBJECTIVES, AND METHODS
Goal
The motive for this project is to answer the question of the cost-utility of
screening for prostate cancer.  A cost-utility considers the ratio of costs of diagnosis and
treatment of prostate cancer to the utilities of outcomes.   The cost-utility ratios of the
course of the disease includes screening and the course of the disease that does not
include screening will be compared.  There is a problem with screening utilities and
outcomes. There is documentation of the utilities of the outcome of treatment.  However,
to date, there is no documentation as to a difference in the outcomes when an individual
is screened for prostate cancer and when he is not.  Hence, the goal is to study the costs
of diagnosis and treatment per person of screening versus costs of diagnosis and
treatment per person of not screening.  In addition, various parameters in the model will
be studied to demonstrate the effects of these parameters on the costs per person.  The
model is constructed to accommodate utility data when the data becomes available.
Objectives
The specific objectives of this study are:
" to determine if there is a difference in the costs of diagnosis and
treatment with respect to screening or not screening.
" to examine the relationship of the cost of treatment as a result of
19
screening to the cost of treatment as a result of not screening.
" to determine the effect of improvements in PSA test parameters
(sensitivity and specificity) for the screening test.
" to determine the utility/effectiveness difference that favors
screening with an “incremental cost-effectiveness ratio” less than
$50,000 per quality adjusted life year (QALY).
Design
A decision-analysis model was developed to compare the costs associated with
the diagnostic work-up and treatment following screening, and the diagnostic work-up
and treatment following the presentation of symptoms.  A cost analysis was used to
differentiate the two alternatives.  The costs involved will occur over time.  To determine
the costs over time a Markov model was utilized.  In order to demonstrate the confidence
that there is a difference in the alternatives, a Monte Carlo analysis of the Markov model
was implemented.  Most probability estimates were generated from the SEER and CDC
databases.  A few probability estimates were generated from data in the literature search. 
The most current years of data available at the time of publication were incorporated in
the analysis.  Sensitivity analyses were performed on the variables outlined in the
objectives.  The sensitivity analyses utilized ranges that were possible, but not
necessarily probable.  The calculations, Markov analysis, and Monte Carlo simulation
were performed using TreeAge Pro Suite 2005, Release 0.8 (TreeAge Software, Inc.,
Boston, MA, 2004), a decision analysis software program.  The statistical analysis was
performed using R, Release 2.2.1 and SPSS for Windows, Release 8.0.0 (SPSS, Inc.,




The cohort is comprised of 50 year old males with no known cancer of the
prostate.  At this age the risk of developing prostate cancer increases significantly.  The
age range for this study was 50 to 85 years old.  It is recommended that since prostate
cancer is such a slow growing cancer, if the life expectancy is less than ten years, there is
no need to screen, or perhaps even treat.
The States of Nature
When performing a Markov analysis, the states of nature must be identified.  An
initial bubble diagram was developed.  (See Figure 2.)  It included as states of nature: no
cancer and no symptoms, no cancer and symptoms, cancer and no symptoms, cancer and
symptoms, cancer and treatment, cancer and no treatment, death from prostate cancer,
and death for other causes.  Although these seemed to be the states appropriate to this
model, some simplification was indicated.  If there are no symptoms, then one would not
know if there were cancer or not.  Also, in the case known cancer, the state can be
reduced to cancer with treatment and cancer with no treatment.  And finally, death from
prostate cancer or death from another cause can be pooled in just death.  Figure 3
diagrams the model used in the Markov analysis.
21
 
Figure 2. The initial bubble diagram demonstrates the complexity of the states of
nature.
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Figure 3. This bubble diagram illustrate the knowable states of nature and their
relationships.
The Markov Model
The decision tree for the model is illustrated in figure 4.  The Markov nodes are
the decision to screen and the decision not to screen.  See figure 5.  The sub-trees beneath
both these nodes branch into the four states of nature that the model is built upon.  See
figure 6.  This is necessary in order to evaluate the Markov model for the four states of
nature.  Note that the box is the decision node, that the circles with the “M” in them are
Markov nodes, that the open circles are chance nodes, and the triangles are terminal
nodes.  At the terminal nodes, the flow loops back to the designated state of nature.
23
Figure 4. Cost-Comparison Markov Model.
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Figure 5. This is the initial decision in the model, the decision to screen or to not
screen.
Figure 6. The states of nature are applied to each Markov node.
As illustrated in Figure 7, the branches from the nodes “Cancer/No Treatment”
and “Cancer/Treatment” are identical for both “Screen” and No Screen” Markov nodes.  
A difference occurs in the “Screen/No Known Cancer Node.”  The node branches into
“Screen +” and Screen -.”  See Figure 8.  The “No Screen/No Known Cancer Node” and
the “Screen/No Known Cancer Node/Screen -” have identical sub-trees which include
“remain unknown,” “develop symptoms,” “death PC,” and “death other.”  This is
illustrated in Figure 9.  In Figure 10 the “work-up” sub-branches are highlighted.  These
branches are a result of either screening positive or developing symptoms.  Finally, the
sub-tree displayed in Figure 11 is the portion of the model where the effect of screening
25
occurs.
Costs occur at the screening nodes, work-up nodes, and the treatment nodes.  One
cycle of the model is equivalent to one year elapsing.  The analysis occurs over 35 years,
ages 50 to 85.  The reason the model ends at 85 years is that the data was not available to
extrapolate the table used in the TreeAge® software.
Figure 7. The sub-trees of Cancer/Treatment and Cancer/No Treatment are identical
for both alternatives.
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Figure 8. This figure illustrates the major difference in the sub-trees of the Markov
nodes.  The Screening chance node only exists in the Screen decision
branch.
27
Figure 9. This figure illustrates the similarities in the sub-trees where the model is
depending on symptoms to identify disease.
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Figure 10. At these nodes in the model another similarity is found.  The sub-trees at
this level are focused on the results of the diagnostic work-up.
29
Figure 11. This figure details the branches for the state of nature of No Known
Cancer of the decision node Screen.
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Model Inputs
Incidence of Prostate Cancer
The incidence rates were obtained from the SEER database.56  Table 4 contains
the data obtained from the SEER database.  The incidence rate changes with age.  A table
was used in the model in order to facilitate the changes in incidence as the cohort aged. 
The age-conditional probabilities of developing prostate cancer57 in the table used in the
model were extrapolated for each year by use of the hazard function.  (See Appendix
Bamd C.)
Table 4





50 - 55 0..00765
55 - 60 0.01760
60 - 65 0.03051
65 - 70 0.04570
70 - 75 0.05396
75 - 80 0.05413
80 - 85 0.04582
Death Rates
Table 6 and Table 7contain each probability that someone entering the age group
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at the lower age died before getting to the next age group.  The data was obtained from
the SEER data base.  The overall death rates are in Table 7.  The data for overall death
rates came from the CDC mortality databases.  Both tables list  probabilities.  The age-
conditional probabilities of dying of prostate cancer58 in the table used in the model were
extrapolated for each year by use of the hazard function.  (See Appendices B and C.) 
Being an incidence rate for the various age intervals, the overall probabilities of death in
the analysis were extrapolated by an even distribution across the interval.  The death rate
for other causes was determined by subtracting the probability of dying from prostate
cancer from the overall probability of death for that age interval.
Table 5.





50 - 54 0.00016
55 - 59 0.00046
60 - 64 0.00113
65 - 69 0.00245
70 - 74 0.00481
75 - 79 0.00875
80 - 84 0.01482
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Table 6.




50 - 54 0.006535
55 - 59 0.009618
60 - 64 0.014760
65 - 69 0.022659
70 - 74 0.035330
75 - 79 0.055227
80 - 84 0.086528
Other Inputs
The incidence of BPH was taken from Table 2, Incidence of LUTS/BPH.  The
data in this table is the incidence rate across the age intervals and is survival adjusted. 
The incidence rates of LUTS/BPH  in the analysis were extrapolated across the intervals
using the hazard function.  (See Appendices B and C.)  The screening cost was set at
$25.70, the first year treatment cost was set at $11,000.00, the diagnostic work-up
(biopsy) was set at $900.00, and the sensitivity and the specificity of the PSA test were
0.8 and 0.7, respectively.  The initial values and the equations used to obtain the
probabilities and payoffs within the decision tree are in Appendix A and Appendix B. 
The ranges used in the Markov sensitivity analyses are in Table 8.
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Table 7.
Range of Values by Variable Used in the Sensitivity Analyses
Variable Low High
First Year Treatment Costs 11000 50000
Incidence Rate of Prostate Cancer 0.001 0.02
Treatment Factor 0 1
PSA Sensitivity 0.8 1.0
PSA Specificity 0.7 1.0
The “Treatment Factor” is introduced to simulate the relationship of the expected costs
between “screening” and “not screening.”  The “Treatment Factor” (TF) is a multiplier
that forces the first year treatment costs for “screening” to 0 as the first year treatment
costs for “not screening” goes to double its original value.  The assumption behind the TF
is that if through screening more organ confined disease is found and the morbidities are
decreased, then the first year treatment costs will be lower for screening than the first
year treatment costs of without screening.
The incremental cost-effectiveness ratio (ICER) is the ratio of the difference in
costs divided by the “willingness to pay” amount.  The “willingness to pay” amount is
$50,000.  The ICER in this model is calculated by subtracting the “roll-back” cost





Beginning at the baseline values listed in Appendix A and progressing through
the Markov analysis using the changes due to age as listed in Appendix B, the results are
listed in Table 9 and displayed in Figure 12.  Utilities were not considered in this portion
of the analysis.  The Markov optimal cost was $252 which was the rollback amount for






A Monte Carlo simulation was undertaken.  The cohort was made up of 2,000,000
men from age 50 to 85 years.  1,000,000 men were screened and 1,000,000 men were not
screened.  The mean and standard deviation of the cost of those screened were $10,713
and $4,556, respectively.  The mean and standard deviation of the cost of those not
screened were $254 and $713, respectively.  An analysis of variance was conducted on
the data from the simulation.  The F statistic was 5145997.2 with a significance of 0.000. 
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The distributions of screening and no screen are illustrated in graphs 1 and 2,
respectively.  The distribution of screening is slightly skewed, where as the distribution
for not screening is strongly skewed.
Figure 12. The Markov analysis roll-back indicates that at baseline, not screening is
less costly.  The “P = 1.000" is the probability of choosing “No Screen.”
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Graph 1. Histogram of the cost per person results of the Monte Carlo simulation
associated with screening by the frequency of occurrence of that cost for a
Cohort of 1,000,000 Males.
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Graph 2. Histogram of the cost per person results of the Monte Carlo simulation
associated with not screening by the frequency of occurrence of that cost
for a Cohort of 1,000,000 Males.
One-Way Sensitivity Analyses
One-way sensitivity analyses were performed to explore the parameters that have
an effect on the cost per person in the model.  The sensitivity of the first year treatment
costs (FYTC) was analyzed by increasing this cost incrementally from $11,000 to
$50,000.  The assumption here is that as the First Year Treatment Costs increase, the
effect of the costs of screening and work-up is diminished.  Table 10 and Graph 3 display
the results.  The resulting change in costs by alternative increased at different rates.  The
costs per person associated with screening rose from $10,717 to $16,896 and the costs
per person associated with not screening rose from $252 to $335.
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Table 9.
First Year Treatment Costs by  Screening Associated Costs and Not Screening
Associated Costs






















Graph 3. This is a graph of the of increases in first year treatment costs by the
expected value of the total costs of screening and not screening.
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Next, the sensitivity to increases in the incidence rate (IR) in terms probabilities
were analyzed.  If the IR is increased then it is assumed again that the increased treatment
costs could reduce the effect of the screening and work-up costs.  The IR was increased
incrementally from 0.001 to 0.020.  Table 11 and Graph 4 display the results.  The
resulting change in costs by alternative increased at different rates.  The costs per person
associated with screening rose from $9,847.43 to $12,200.10 and the costs per person
associated with not screening rose from $150.79 to $517.25.
Table 10.
Incidence Rate expressed as a probability by  Screening Associated Costs and Not
Screening Associated Costs























Graph 4. This is a graph of the of increases in incidence rates expressed as
probabilities by the expected value of the total costs of screening and not
screening.
The sensitivity of the treatment factor (TF) explores the effect of lowering the
FYTC for screened persons at the same time increasing the FYTC for persons not
screened.  In effect the “screened” FYTC goes to zero as the “not screened” FYTC
doubles. This assumes treatment cost would be lower if the disease is discovered earlier. 
The TF was increased incrementally from 0 to 1.  Table 12 and Graph 5 display the
results.  The costs per person associated with screening declined from $10,717 to $8,974
and the costs per person associated with not screening rose from $252 to $275.  There




Treatment Factor by  Screening Associated Costs and Not Screening Associated Costs






















Graph 5. This is a graph of the of increases the treatment factor, that forces the
costs associated with screening to zero and the costs associated with not
screening to double, by the expected value of the total costs of screening
and not screening.
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The next sensitivity analyses is that of an improving PSA test sensitivity (TP). 
The sensitivity of a diagnostic test is the ratio of those that test positive and have the
disease to the total of those that have the disease.59  The true positive ratio was increased
incrementally from 0.8 to 1.0.  Table 13 and Graph 6 display the results.  The costs per
person associated with screening rose from $10,717 to $10,986, and the costs per person
associated with not screening remained at $252.
Table 12.
True Positive by  Screening Associated Costs and Not Screening Associated Costs























Graph 6. This is a graph of the of improvements in sensitivity of the screening test
by the expected value of the total costs of screening and not screening.
The next sensitivity analyses is that of an improving PSA specificity (TN).  The
specificity of a lab test is the percentage of those that test negative and do not have the
disease compared to the total of those that do not have the disease.60  The true negative
ratio was increased incrementally from 0.7 to 1.0.  Table 14 and Graph 7 display the
results.  The costs per person associated with screening declined from $10,971.73 to
$2,882.30 and the costs per person associated with not screening remained $261.75.   
There was no convergence before the TN reached 100%.
Table 13.
True Negative by  Screening Associated Costs and Not Screening Associated Costs
























Graph 7. This is a graph of the of improvements in specificity of the screening test
by the expected value of the total costs of screening and not screening.
Incremental Cost-Effectiveness Ratio
The incremental cost-effectiveness ratio calculation can describe the relationship
between the utilities of the alternatives.  The ICER is the difference in costs of the
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alternatives divided by the differences in the utilities/effectiveness.   The benchmark for
the ICER is the amount that we are willing to pay for an additional QALY, or in other
words the “willingness-to-pay” (WTP) amount for an additional QALY.  The ICER is an
important measure of medical ethics.  It defines whether we ought to do something or
not.  With respect to this two-alternative model, the equation for the ICER is Figure 13. 
A corollary to this is illustrated in Figure 14.  The difference between the effectiveness of











2 1− = −
Figure 14. Calculation of expected utility/effectiveness differences.
The differences in costs divided by the WTP in this model, before adjustments in






the utilities/effectiveness must be greater than 0.209 in order to facilitate the ICER to be
less than the WLP.  An improvement in a parameter should lower this target ratio.  It is
anticipated that if the differences in costs are reduced, then this ratio decreases and the
cost-effectiveness improves.  In the sensitivity analysis of the treatment factor (TF), the
cost per person of “screen” is $8,974 and the cost per person of “no screen” is $275. The
ratio of cost difference to WTP is 0.174.  The most significant parameter change is the
improvement in the specificity of the PSA.  the cost per person of “screen” is $2,788 and
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the cost per person of “no screen” was $252. The ratio of cost difference to WTP is





At baseline, screening costs more than not screening.  The estimates of cost and
probabilities are conservative.  With respect to the parameters examined in the model,
marked improvement in all of them is required to facilitate a cost-effective case for
screening.  If in the future, as a result of the research currently being conducted in Europe
it can be shown that the utilities are sufficiently higher, the first year treatment costs
sufficiently lower, and the PSA specificity is sufficiently improved with respect to
screening, then the cost-utility of screening would indicate that screening is the course of
action.
Discussion
Prostate cancer is expensive.  Prostate diseases in general are just about
guaranteed if a man lives long enough.  In the case of prostate cancer, a significant
amount of the countries wealth is spent on this disease.
The screening and diagnostic procedures employed in the diagnosis of prostate
cancer are not perfect.  Using the example of the screened 1,000,000 man cohort and a
PSA sensitivity of 0.8, at age 50 there were 307 false negatives, or men that have prostate
cancer, but screened negative.  Again using the cohort, there were 299,540 that screened
positive when they didn’t have the cancer.  The costs associated with screening come
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from the fact that the next step in the process is to have a biopsy.  This means that
300,000 biopsies would be performed unnecessarily.  In addition, if the sextant biopsy is
performed, there are problems with its sensitivity, i.e. some false negatives.
An interesting point is the differences in thinking about treatment.  Because all of
the treatment modalities carry devastating complications, not all men are willing to be
treated.  Some elect to do “watchful waiting.”  This does not mean that they do nothing. 
They are followed via additional screening, biopsies, MRI, CT scans, etc.
The three groups that provide guidelines for screening, the American Cancer
Society, the University of Michigan Health System, and the U.S. Preventive Services
Task Force have different guidelines for screening.  Only the American Cancer Society
recommends routine annual screening.  There is agreement that a man age fifty or greater
should be educated about screening and its implications, both good and bad.
The data used in the model were conservative.  $900 for the work-up cost only
included the biopsy.  Many times MRI and CT are included in the work.  Sometime
multiple biopsies are performed.  The specificity and the sensitivity of the PSA test used
in the model are the maximums reported.  They vary by age, race, national origin, and
ethnicity.
The model lends itself to further study.  The model is set up to accept data from
future research results.  As the sensitivity and specificity of the screening test changes,
the parameters in the model can be altered.  The current optimal sensitivity and
specificity for the PSA test were used in the model.  The model was constructed to
accommodate differences in these parameters for age.  A utility function that considers
the “willingness-to-pay” amount can easily be adapted.  Cost-effectiveness can easily be
extracted from the analysis.  The model centers around age in men.  However, the model
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is also adaptable to high-risk groups of men who are differentiated by race, ethnicity, or
national origin.  The may be a better use of the model.
The results demonstrate that parameter improvements can effect the differences in
utilities that are necessary to facilitate a case for screening cost-effectiveness.  If
screening can reduce the morbidities and mortality and thus reduce the cost of treatment,
then the difference in utilities can be lower.  It is demonstrated that the improvement in
the screening test specificity can reduce the difference target by a large amount.  In fact,
improving specificity is the single best method of reducing the need for a large
effectiveness difference.  The most concrete conclusion that can be made is that
screening costs more than not screening.  Due to the unnecessary biopsies and work-ups,
the costs are significantly different.
The cost-utility of prostate screening is questionable.  The incremental cost-
effectiveness can be improved by three things.  The cost of treatment is going to have to
be significantly lower for those that are screened.  The specificity of screening must
improve significantly.  And, the utilities/QALYs for those screened will have to be
higher than the utilities/QALYs for those not screened.  Because of the negative
outcomes of screening, this may or may not be the case.  The  European Randomized
Study of Screening for Prostate Cancer will have data available to ascertain this
information.  In the absence of good outcome data, It may come down to a medically
ethical or a moral decision to screen.
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Limitations of Study
At this point, the only thing that is for certain is that screening costs more; the rest
of the model is speculation.  Without the outcomes data necessary to complete the
analysis, the analysis merely sets goals for the data.  Also, the actual data used in the
model is conservative.  The specifications for the utilities, the specificity, and the
treatment costs are probably much tighter.  The analysis does not take into consideration
that the PSA specificity varies by age, race, and ethnicity.  It is assumed in the model that
cost will be lower for those that are screened.  The literature shows that because one will
probably die of something else before dying of prostate cancer, the lower cost of
treatment may never be realized.  With respect to the utilities, it is assumed that the large
contingent of the cohort that is false positive and undergoes biopsy will continue to rate
the utilities high.  Good outcome and utility data will improve the integrity of the
conclusions drawn from this model.
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Name Description Formula Value
Age Age _stage+SA 50
BPHS BPH Symptom Incidence Rate tPP[Age;7] 0.001386
CT Completed Treatment Counter 0
DO Death Rate All Other tPP[Age;5] 0.001343
DP Death Rate Prostate Cancer tPP[Age;4] 0.000032
FN False Negative 1-TP 0.2
FP False Positive 1-TN 0.3
FYTC First Year Treatment Cost 11,000
IR Incidence Rate per 100000 tPP[Age;1] 0.001535
Neg Negative Screen ((FN*IR)+(TN*(1-IR))) 0.699233
NT No Treatment Rate (1-DP-DO)*0.119 0.118844
NT1 No Treatment (1) (1-DP-DO)/2 0.499347
Pos Positive Screen ((TP*IR)+(FP*(1-IR))) 0.300767
SA Starting Age 50
SC Screening Cost tPP[Age;6] 25.7
SDR Symptom Development Rate BPHS+(IR*0.5) 0.002153
TCN Treatment Cost (No Screen) FYTC+(TF*FYTC) 11,000
TCS Treatment Cost (Screen) FYTC-(TF*FYTC) 11,000
TF Treatment Factor 0
TN True Negative (Specificity) tPP[Age;3] 0.7
TP True Positive (Sensitivity) tPP[Age;2] 0.8
TR Treatment Rate (1-DP-DO)-NT 0.879849
TR1 Treatment (1) (1--DP-DO)/2 0.499379
WUC Work Up Cost 900
WUNNS Work Up Negative No Screen (1-IR) 0.998465
WUNSN Work Up Negative Screen Negative (TN*(1-IR))/((FN*IR)+(TN*(1-IR))) 0.999561
WUNSP Work Up Negative Rate Screen Positive (FP*(1-IR))/((TP*IR)+(FP*(1-IR))) 0.995918
WUPNS Work Up Positive No Screen IR 0.001535
WUPSN Work Up Positive Screen Negative (FN*IR)/((FN*IR)+(TN*(1-IR))) 0.000439




Index IR TP TN DP DO SC BPHS
50 0.001535 0.8 0.7 0.000032 0.001343 25.7 0.001386
51 0.001535 0.8 0.7 0.000032 0.001343 25.7 0.001386
52 0.001535 0.8 0.7 0.000032 0.001343 25.7 0.001386
53 0.001535 0.8 0.7 0.000032 0.001343 25.7 0.001386
54 0.001535 0.8 0.7 0.000032 0.001343 25.7 0.001386
55 0.003545 0.8 0.7 0.000092 0.002024 25.7 0.002618
56 0.003545 0.8 0.7 0.000092 0.002024 25.7 0.002618
57 0.003545 0.8 0.7 0.000092 0.002024 25.7 0.002618
58 0.003545 0.8 0.7 0.000092 0.002024 25.7 0.002618
59 0.003545 0.8 0.7 0.000092 0.002024 25.7 0.002618
60 0.006178 0.8 0.7 0.000226 0.003198 25.7 0.003988
61 0.006178 0.8 0.7 0.000226 0.003198 25.7 0.003988
62 0.006178 0.8 0.7 0.000226 0.003198 25.7 0.003988
63 0.006178 0.8 0.7 0.000226 0.003198 25.7 0.003988
64 0.006178 0.8 0.7 0.000226 0.003198 25.7 0.003988
65 0.009312 0.8 0.7 0.000490 0.005073 25.7 0.004845
66 0.009312 0.8 0.7 0.000490 0.005073 25.7 0.004845
67 0.009312 0.8 0.7 0.000490 0.005073 25.7 0.004845
68 0.009312 0.8 0.7 0.000490 0.005073 25.7 0.004845
69 0.009312 0.8 0.7 0.000490 0.005073 25.7 0.004845
70 0.011033 0.8 0.7 0.000964 0.008160 25.7 0.006989
71 0.011033 0.8 0.7 0.000964 0.008160 25.7 0.006989
72 0.011033 0.8 0.7 0.000964 0.008160 25.7 0.006989
73 0.011033 0.8 0.7 0.000964 0.008160 25.7 0.006989
74 0.011033 0.8 0.7 0.000964 0.008160 25.7 0.006989
75 0.011068 0.8 0.7 0.001756 0.013136 25.7 0.007780
76 0.011068 0.8 0.7 0.001756 0.013136 25.7 0.007780
77 0.011068 0.8 0.7 0.001756 0.013136 25.7 0.007780
78 0.011068 0.8 0.7 0.001756 0.013136 25.7 0.007780
79 0.011068 0.8 0.7 0.001756 0.013136 25.7 0.007780
80 0.009337 0.8 0.7 0.002982 0.021145 25.7 0.006525
81 0.009337 0.8 0.7 0.002982 0.021145 25.7 0.006525
82 0.009337 0.8 0.7 0.002982 0.021145 25.7 0.006525
83 0.009337 0.8 0.7 0.002982 0.021145 25.7 0.006525
84 0.009337 0.8 0.7 0.002982 0.021145 25.7 0.006525
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Appendix C
Equation Used In Extrapolation
For developing prostate cancer: p(developing disease that year) = 1 - (1 - p(developing the disease by
the 5th year)) ^ 0.2)
For dying from prostate cancer: p(dying from the disease that year) = 1 - (1 - p(dying from the disease
by the 5th year)) ^ 0.2)
For dying from another cause: p(dying from another cause that year) = 1 - ((1 - p(dying from any
cause by the 5th year) - (dying from the disease by the 5th year)) ^ 0.2)
For developing LUTS/BPH: p(developing disease that year) = 1 - (1 - p(developing the disease by
the 5th year)) ^ 0.2)
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